Literature DB >> 29443117

CRISPR-Cas-related technologies in basic and translational liver research.

Chun-Qing Song1, Wen Xue1,2.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29443117      PMCID: PMC6172947          DOI: 10.1038/nrgastro.2018.11

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

Review 1.  Genome editing. The new frontier of genome engineering with CRISPR-Cas9.

Authors:  Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2014-11-28       Impact factor: 47.728

2.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration.

Authors:  Keiichiro Suzuki; Yuji Tsunekawa; Reyna Hernandez-Benitez; Jun Wu; Jie Zhu; Euiseok J Kim; Fumiyuki Hatanaka; Mako Yamamoto; Toshikazu Araoka; Zhe Li; Masakazu Kurita; Tomoaki Hishida; Mo Li; Emi Aizawa; Shicheng Guo; Song Chen; April Goebl; Rupa Devi Soligalla; Jing Qu; Tingshuai Jiang; Xin Fu; Maryam Jafari; Concepcion Rodriguez Esteban; W Travis Berggren; Jeronimo Lajara; Estrella Nuñez-Delicado; Pedro Guillen; Josep M Campistol; Fumio Matsuzaki; Guang-Hui Liu; Pierre Magistretti; Kun Zhang; Edward M Callaway; Kang Zhang; Juan Carlos Izpisua Belmonte
Journal:  Nature       Date:  2016-11-16       Impact factor: 49.962

3.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.

Authors:  Hao Yin; Chun-Qing Song; Sneha Suresh; Qiongqiong Wu; Stephen Walsh; Luke Hyunsik Rhym; Esther Mintzer; Mehmet Fatih Bolukbasi; Lihua Julie Zhu; Kevin Kauffman; Haiwei Mou; Alicia Oberholzer; Junmei Ding; Suet-Yan Kwan; Roman L Bogorad; Timofei Zatsepin; Victor Koteliansky; Scot A Wolfe; Wen Xue; Robert Langer; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2017-11-13       Impact factor: 54.908

Review 4.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

5.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses.

Authors:  Dan Wang; Haiwei Mou; Shaoyong Li; Yingxiang Li; Soren Hough; Karen Tran; Jia Li; Hao Yin; Daniel G Anderson; Erik J Sontheimer; Zhiping Weng; Guangping Gao; Wen Xue
Journal:  Hum Gene Ther       Date:  2015-07       Impact factor: 5.695

6.  RNA targeting with CRISPR-Cas13.

Authors:  Omar O Abudayyeh; Jonathan S Gootenberg; Patrick Essletzbichler; Shuo Han; Julia Joung; Joseph J Belanto; Vanessa Verdine; David B T Cox; Max J Kellner; Aviv Regev; Eric S Lander; Daniel F Voytas; Alice Y Ting; Feng Zhang
Journal:  Nature       Date:  2017-10-04       Impact factor: 49.962

7.  Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.

Authors:  Chun-Qing Song; Yingxiang Li; Haiwei Mou; Jill Moore; Angela Park; Yotsawat Pomyen; Soren Hough; Zachary Kennedy; Andrew Fischer; Hao Yin; Daniel G Anderson; Darryl Conte; Lars Zender; Xin Wei Wang; Snorri Thorgeirsson; Zhiping Weng; Wen Xue
Journal:  Gastroenterology       Date:  2016-12-10       Impact factor: 22.682

Review 8.  Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes.

Authors:  Gaelen T Hess; Josh Tycko; David Yao; Michael C Bassik
Journal:  Mol Cell       Date:  2017-10-05       Impact factor: 17.970

Review 9.  Applications of the CRISPR-Cas9 system in cancer biology.

Authors:  Francisco J Sánchez-Rivera; Tyler Jacks
Journal:  Nat Rev Cancer       Date:  2015-06-04       Impact factor: 60.716

10.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

  10 in total
  4 in total

1.  In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.

Authors:  Chun-Qing Song; Dan Wang; Tingting Jiang; Kevin O'Connor; Qiushi Tang; Lingling Cai; Xiangrui Li; Zhiping Weng; Hao Yin; Guangping Gao; Christian Mueller; Terence R Flotte; Wen Xue
Journal:  Hum Gene Ther       Date:  2018-05-14       Impact factor: 5.695

2.  CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling.

Authors:  Haiwei Mou; Deniz M Ozata; Jordan L Smith; Ankur Sheel; Suet-Yan Kwan; Soren Hough; Alper Kucukural; Zachary Kennedy; Yueying Cao; Wen Xue
Journal:  Genome Med       Date:  2019-04-16       Impact factor: 11.117

Review 3.  Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.

Authors:  Huimin Kong; Enguo Ju; Ke Yi; Weiguo Xu; Yeh-Hsing Lao; Du Cheng; Qi Zhang; Yu Tao; Mingqiang Li; Jianxun Ding
Journal:  Adv Sci (Weinh)       Date:  2021-10-19       Impact factor: 16.806

Review 4.  CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity.

Authors:  Tao Xu; Li Li; Yu-Chen Liu; Wei Cao; Jia-Si Chen; Shuang Hu; Ying Liu; Liang-Yun Li; Hong Zhou; Xiao-Ming Meng; Cheng Huang; Lei Zhang; Jun Li; Huan Zhou
Journal:  Int J Biol Sci       Date:  2020-06-01       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.